Daiken Biomedical Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Jan '26 Jan 29, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	21,628	10,860	-	-
Enterprise Value	16,584	9,874	-	-
Last Close Price	26.70	17.34	-	-
PE Ratio	61.11	101.90	-	-
PS Ratio	12.13	7.97	-	-
PB Ratio	4.04	8.31	-	-
P/TBV Ratio	4.05	8.33	-	-
P/FCF Ratio	73.28	215.06	-	-
P/OCF Ratio	73.13	209.86	-	-
EV/Sales Ratio	9.30	7.25	-	-
EV/EBITDA Ratio	59.38	64.48	-	-
EV/EBIT Ratio	60.77	66.31	-	-
EV/FCF Ratio	56.19	195.53	-	-
Debt / Equity Ratio	0.00	0.00	1.12	0.60
Debt / EBITDA Ratio	0.07	0.01	1.35	1.21
Debt / FCF Ratio	0.07	0.05	2.63	3.27
Asset Turnover	0.48	1.19	1.87	-
Inventory Turnover	1.78	1.99	1.71	-
Quick Ratio	17.91	5.36	0.80	1.23
Current Ratio	19.43	6.56	1.64	2.17
Return on Equity (ROE)	8.09%	13.71%	67.55%	-
Return on Assets (ROA)	4.63%	8.15%	20.01%	-
Return on Invested Capital (ROIC)	195.95%	55.95%	94.00%	77.31%
Return on Capital Employed (ROCE)	5.10%	11.40%	68.80%	38.90%
Earnings Yield	1.24%	0.98%	-	-
FCF Yield	1.36%	0.46%	-	-
Dividend Yield	1.51%	2.33%	-	-
Payout Ratio	217.98%	2.89%	87.59%	-
Buyback Yield / Dilution	-77.82%	-95.20%	-44.34%	-
Total Shareholder Return	-76.31%	-92.87%	-44.34%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.